Akumin Inc

Akumin — Q3 2021 Earnings Presentation

31 slides from Akumin's earnings presentation, December 2021

  1. Slide 1: Corporate Presentation

    Akumin Inc. Corporate Presentation December 2021 Riadh Zine, Chairman & Co-CEO Rhonda Longmore-Grund, President & Co-CEO Bill Larkin, Chief Financial Officer

  2. Slide 2: Disclaimer and Disclosure

    Disclaimer and Disclosure Forw ard-Looking Statements This presentation may contain forward-looking information or forward-looking statements w ithin the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-loo

  3. Slide 3: Today's Presenters

    Today’s Presenters Riadh Zine Rhonda Longmore-Grund Bill Larkin Chairman of the Board and Co-CEO President and Co-CEO Chief Financial Officer • Akumin’s CEO since it started in 2014, now • Previously President and Chief Executive • Previously Executive Vice President & Chief serves as Chairman and C

  4. Slide 4: Akumin At a Glance

    Akumin At a Glance • #2 overall radiology services provider: ~2 million procedures/year in 46 states • #1 provider of PET/CT services • #2 provider of MRI services • #2 fixed site clinic locations • #1 mobile radiology provider • #2 provider of radiation therapy services to U.S. hospitals treating m

  5. Slide 5: Long-Standing Health System Relationships

    Long-Standing Health System Relationships The Nation’'s Largest and Leading Health Systems Radiology & Oncology • 30+ year history of successful hospital partnerships • ~1,000 hospital relationships within Radiology and Oncology networks • Serving 25 of the top 30 hospitals in the nation • Deep part

  6. Slide 6: Flexible Approach Focused on Fixed Site Development & Growth

    Flexible Approach Focused on Fixed Site Development & Growth • Comprehensive solutions Mobile On-Campus Outpatient Outpatient Fixed Sites Fixed Sites Networks delivered through a flexible • Market or regional approach to partnership • Shared platform, part- • Within or adjacent to • Convenient locat

  7. Slide 7: Outpatient-Focused Platform

    Outpatient-Focused Platform ~95% of the company’s overall revenue is derived from outpatient procedures Overall Payor Mix Hospital Mix of Outpatient (% of Revenue) (% of Revenue) • 50% of revenue is received Inpatient via third party and Revenue 3% government payers, for which we bill outpatient Med

  8. Slide 8: Diverse Service Lines and Modalities

    Diverse Service Lines and Modalities • Continued diversification of Service Lines revenue between Radiology (% of Revenue) and Oncology divisions Radiology Procedure Mix (% of Revenue) • Akumin provides a full suite of radiology and oncology 20% 20% services with a focus on high- growth and high-val

  9. Slide 9: A Powerhouse in Radiology

    A Powerhouse in Radiology Total Radiology Volume/Year Akumin is the nation’s #2 overall radiology company, (Pro Forma) 2,134,415 with more than 2 million patient visits per year 2,006,759 Akumin is the nation’s #2 MRI provider 1,916,412 • A critical diagnostic tool for complex health conditions and

  10. Slide 10: The Nation's #2 Partner in Radiation Therapy Services with Hospitals

    The Nation’s #2 Partner in Radiation Therapy Services with Hospitals • ~2/3 of cancer patients receive radiation • Akumin excels in Joint Venture partnerships therapy as part of their cancer treatment with hospitals and physicians and in delivering this complex clinical service line • Akumin special

  11. Slide 11: Uniquely Positioned as a Hospital Partner of Choice

    Uniquely Positioned as a Hospital Partner of Choice Patient Care Continues to Coalesce As Hospitals Shift to Outpatient Services, Around the Hospital Network Akumin is Their Most Experienced 91% of final-year medical residents report that Partner they prefer to be an employee of a hospital Hospital

  12. Slide 12: Expert Solutions Provider As Radiology Outpatient Migration Accelerates

    Expert Solutions Provider As Radiology Outpatient Migration Accelerates Positive forces on radiology volume growth • Population change, consumerism, disease prevalence, technology; dampened by continued payer actions Hospital Imperative Deploy a full suite of services to Outpatient migration continu

  13. Slide 13: Strategic Partner in a Cancer Care Market Demanding Efficiency and Collaboration

    Strategic Partner in a Cancer Care Market Demanding Efficiency and Collaboration COVID-19 impacts are ongoing and evolving Cancer incidence, overall, continues to grow • Many cancer screening monthly volumes have • Number of newly diagnosed cancers per year is projected returned to pre-pandemic leve

  14. Slide 14: Significant Market Opportunity With Favorable Industry Trends

    Significant Market Opportunity With Favorable Industry Trends Radiology Oncology ~$16-17 billion ~$3 billion Estimated Market Size Estimated Radiation Therapy Market Size Radiology is essential to healthcare delivery and utilized in Radiation therapy is essential to virtually all clinical specialtie

  15. Slide 15: Growth Strategy: Driving Shareholder Value

    Growth Strategy: Driving Shareholder Value Deliver Enterprise Drive New Growth in Drive New Growth in Enterprise Organic Growth Radiology Oncology Transformation Market, Partner Market Leadership & Deepen Cancer Care Strategic Shift & Market & Company Health Performance Value Proposition Differentia

  16. Slide 16: Enabling Value Creation Via Operational Platform Transformation

    Enabling Value Creation Via Operational Platform Transformation We are building innovative standardization in • Patient journey • Clinical workflow • Data Focused on creating a scalable service Patient delivery platform Experience Because delivering exceptional patient engagement and experiences is

  17. Slide 17: Integration Cost Synergy Potential

    Integration Cost Synergy Potential Integration Cost Synergy Potential The $23 million in estimated cost synergies are related to phase 1 and equipment maintenance overhaul in phase 2. More upside in cost savings expected to arise from a number of initiatives as outlined in both phase 2 and phase 3.

  18. Slide 18: Financial Performance

    Financial Performance

  19. Slide 19: Radiology Volume Trends – Pro Forma

    Radiology Volume Trends – Pro Forma • Same Store MRI Volume Growth: +8.5% in Q3 2021 • Same Store PET/CT Volume Growth: +2.2% in Q3 2021 • Same Store Total Procedures Volume Growth: +8.9% in Q3 2021 Same Store Volume Growth Total Volumes MRI PET/CT Total Procedures 19

  20. Slide 20: Oncology Volume Trends – Pro Forma

    Oncology Volume Trends – Pro Forma • Same Store Patient Start Volume Growth: 10.1% in Q3 2021 • Patient Start Volume has returned to pre-Covid (2019) levels • Revenue/Patient Start is higher than pre-Covid (2019) levels Same Store Patient Start Volume Growth Total - Patient Starts Volume1 Total - Re

  21. Slide 21: Financial Performance Trend Statutory (As Reported) and Pro Forma

    Financial Performance Trend Statutory (As Reported) and Pro Forma Revenue1 Adjusted EBITDA2 ($M) ($M) Maintenance CAPEX3 Growth CAPEX3 ($M) ($M) 1 P ro forma includes A lliance O ncology of A rizona (div ested Q 4 2021) w hich contributed $ 13.2M of Rev enue TTM and Interv entional Div ision (div es

  22. Slide 22: Segment Financial Performance Statutory & Pro Forma

    Segment Financial Performance Statutory & Pro Forma Q3 2021 Q3 2021 YTD ($ in M) RAD ONC Corp Total ($ in M) RAD ONC Corp Total Revenue $ 95.0 $13.2 $ - $ 108.2 Revenue $228.5 $ 13.2 $ - $ 241.6 % vs prior year 50.3% n/m 71.1% % vs prior year 27.8% n/m 35.2% Adjusted EBITDA $ 16.6 $ 4.9 $ (3.5) $ 18

  23. Slide 23: Guidance & Valuation

    Guidance & Valuation ©)akumin:

  24. Slide 24: 2022 Guidance

    2022 Guidance • Full year of combined enterprise • Positive same store volume across the platform • Strong new customer acquisition as well as retention • Revenue range $760M-$780M • Sept 2021 TTM Revenue of $309M. Includes one month of Alliance acquisition vs twelve months in 2022 guidance. • Adjus

  25. Slide 25: Free Cash Flow Generation

    Free Cash Flow Generation The company expects to generate free cash flows of ~$55mm as per the following assumptions: LTM 2022 2022 • Mid range of the 2022 Sep 30 2021 Midpoint Runrate guidance Adjusted EBITDA(1) $ 42.1 $ 160.6 $ 186.8 (2) • Full deployment of 2022 Less: Growth CAPEX of $59M and Mai

  26. Slide 26: Capital Structure – A Solid Foundation for Growth

    Capital Structure – A Solid Foundation for Growth (US$ millions, unless noted) Strong Alignment Share Price ($) $ 1.70 of Interests Total Shares Outstanding (mm) 89.0 Management and insiders, Equity Value $ 151.3 including Stonepeak, own approximately 40% resulting in Total Secured Debt $ 903.2 stro

  27. Slide 27: Strong Partners Well-Aligned With Shareholders

    Strong Partners Well-Aligned With Shareholders • The support of Stonepeak was integral to the successful completion of the Alliance acquisition and, through its subordinated notes, equity position and warrant holdings, is well-aligned with shareholders as key beneficiaries of Akumin’s future growth.

  28. Slide 28: Thank you!

    Thank you! Riadh Zine, Chairman & Co-CEO Rhonda Longmore-Grund, President & Co-CEO Bill Larkin, Chief Financial Officer

  29. Slide 29: Net Income to Adjusted EBITDA Reconciliation

    Appendix 1: Net Income to Adjusted EBITDA Reconciliation ~AKUMIN" (Restated- (Restated- Note 4) Note 4) Three months Three months Nine months Nine months ended ended ended ended September 30, September 30, September 30, September 30, 2021 2020 2021 2020 Net income (I oss) $ 1, 180 $ (6,376) $ (8, 18

  30. Slide 30: Income Statement

    Appendix 2 Income Statement Three months ended September 30, (Restated-Note 4) Three months ended September 30, Nine months ended September 30, (Restated-Note 4) Nine months ended September 30, ~AKUMIN" 2021 2020 2021 2020 Revenues $ 108, 177 $ 63,213 $ 241,636 $ 178,747 Operating expenses: Cost cl

  31. Slide 31: Balance Sheet

    Appendix Appendix 3: 3: (Restated-Note 4) Balance Balance Sheet ASSETS Sheet September 30, 2021 December 31, 2020 ~AKUMIN" Current assets: Cash $ 55,876 $ 44,396 Acc ounts receilable 135,208 62,259 Prepaid expenses 1 1,815 2,996 Other current assets 3,232 1,435 Total current asset s 206, 131 111 ,08

Akumin — Q3 2021 Earnings Presentation on 6ix